Conv. Plasma
Nigella Sativa

All regdanvimab studies
Meta analysis
study COVID-19 treatment researchRegdanvimabRegdanvimab (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 71% Improvement Relative Risk Ventilation 64% Hospitalization time 9% Regdanvimab for COVID-19  Chae et al.  EARLY TREATMENT Is early treatment with regdanvimab beneficial for COVID-19? Retrospective 124 patients in South Korea (March - May 2021) Lower ventilation with regdanvimab (not stat. sig., p=0.46) Chae et al., Tropical Medicine and Inf.., Mar 2022 Favors regdanvimab Favors control

The Effectiveness of the Use of Regdanvimab (CT-P59) in Addition to Remdesivir in Patients with Severe COVID-19: A Single Center Retrospective Study

Chae et al., Tropical Medicine and Infectious Disease, doi:10.3390/tropicalmed7030051
Mar 2022  
  Source   PDF   All   Meta
35th treatment shown to reduce risk in March 2022
*, now known with p = 0.0000009 from 7 studies, recognized in 27 countries. Efficacy is variant dependent.
Lower risk for hospitalization, progression, and recovery.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
Retrospective 124 hospitalized severe COVID-19 patients receiving oxygen and remdesivir treatment in South Korea. A subgroup of 25 patients also received the monoclonal antibody regdanvimab prior to remdesivir. The regdanvimab subgroup had significantly more oxygen-free days (primary outcome), higher oxygen saturation, less advanced respiratory support, and shorter oxygen supplementation duration compared to the remdesivir alone group.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BA.2, BA.4, BA.5 Haars, ХВВ.1.9.1, XBB.1.9.3, XBB.1.5.24, XBB.1.16, XBB.2.9, BQ.1.1.45, CL.1, and CH.1.1 Pochtovyi.
risk of death, 71.5% lower, RR 0.29, p = 1.00, treatment 0 of 25 (0.0%), control 2 of 99 (2.0%), NNT 49, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of mechanical ventilation, 64.0% lower, RR 0.36, p = 0.46, treatment 1 of 25 (4.0%), control 11 of 99 (11.1%), NNT 14.
hospitalization time, 8.6% lower, relative time 0.91, p = 0.56, treatment mean 14.32 (±6.78) n=25, control mean 15.67 (±11.12) n=99.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Chae et al., 18 Mar 2022, retrospective, South Korea, peer-reviewed, mean age 57.6, 14 authors, study period 1 March, 2021 - 11 May, 2021. Contact: (corresponding author),,,,,,,,,,,,,
This PaperRegdanvimabAll
The Effectiveness of the Use of Regdanvimab (CT-P59) in Addition to Remdesivir in Patients with Severe COVID-19: A Single Center Retrospective Study
Ganghee Chae, Aram Choi, Soyeoun Lim, Sooneun Park, Seungjun Lee, Youngick Ahn, Jinhyoung Kim, Seungwon Ra, Yangjin Jegal, Jongjoon Ahn, Eunji Park, Jaebum Jun, Woonjung Kwon, Taehoon Lee
Tropical Medicine and Infectious Disease, doi:10.3390/tropicalmed7030051
Introduction: Coronavirus disease 2019 (COVID-19) still has a high mortality rate when it is severe. Regdanvimab (CT-P59), a neutralizing monoclonal antibody that has been proven effective against mild to moderate COVID-19, may be effective against severe COVID-19. This study was conducted to determine the effectiveness of the combined use of remdesivir and regdanvimab in patients with severe COVID-19. Methods: From March to early May 2021, 124 patients with severe COVID-19 were admitted to Ulsan University Hospital (Ulsan, Korea) and received oxygen therapy and remdesivir. Among them, 25 were also administered regdanvimab before remdesivir. We retrospectively compared the clinical outcomes between the remdesivir alone group [n = 99 (79.8%)] and the regdanvimab/remdesivir group [n = 25 (20.2%)]. Results: The oxygenfree days on day 28 (primary outcome) were significantly higher in the regdanvimab/remdesivir group [mean ± SD: 19.36 ± 7.87 vs. 22.72 ± 3.66, p = 0.003]. The oxygen-free days was also independently associated with use of regdanvimab in the multivariate analysis, after adjusting for initial pulse oximetric saturation (SpO 2 )/fraction of inspired oxygen (FiO 2 ) ratio (severity index). Further, in the regdanvimab/remdesivir group, the lowest SpO 2 /FiO 2 ratio during treatment was significantly higher (mean ± SD: 237.05 ± 89.68 vs. 295.63 ± 72.74, p = 0.003), and the Kaplan-Meier estimates of oxygen supplementation days in surviving patients (on day 28) were significantly shorter [mean ± SD: 8.24 ± 7.43 vs. 5.28 ± 3.66, p = 0.024]. Conclusions: In patients with severe COVID-19, clinical outcomes can be improved by administering regdanvimab, in addition to remdesivir.
Author Contributions: Conceptualization, G.C., A.C., W.K. and T.L.; Methodology, A.C., E.P. and T.L.; Formal Analysis, A.C., E.P. and T.L.; Data Curation, A.C. and T.L.; Writing-Original Draft Preparation, T.L.; Writing-Review & Editing, G.C., S.L., S.P., S.L., Y.A., J.K., S.R., Y.J., J.A. and J.J. All authors have read and agreed to the published version of the manuscript. Conflicts of Interest: The authors declare no conflict of interest.
Activ, Ly-Cov555, Group; Lundgren, Grund, Barkauskas et al., A neutralizing monoclonal antibody for hospitalized patients with COVID-19, N. Engl. J. Med, doi:10.1056/NEJMoa2033130
Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the treatment of COVID-19-final report, N. Engl. J. Med, doi:10.1056/NEJMoa2007764
Borghesi, Maroldi, COVID-19 outbreak in Italy: Experimental chest X-ray scoring system for quantifying and monitoring disease progression, Radiol. Med, doi:10.1007/s11547-020-01200-3
Choi, Hong, Kim, The association between mortality and the oxygen saturation and fraction of inhaled oxygen in patients requiring oxygen therapy due to COVID-19-associated pneumonia, Tuberc. Respir. Dis, doi:10.4046/trd.2020.0126
Eom, Ison, Streinu-Cercel, Săndulescu, Preotescu et al., mild-to-moderate SARS-CoV-2 infection, doi:10.21203/
Group; Horby, Lim, Emberson, Mafham, Bell et al., Dexamethasone in hospitalized patients with COVID-19, N. Engl. J. Med, doi:10.1056/NEJMoa2021436
Kim, Jang, Hong, Jung, Park et al., Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection, Clin. Ther, doi:10.1016/j.clinthera.2021.08.009
Kim, Kim, Huh, Choi, Kim et al., Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency recommendations for anti-SARS-CoV-2 monoclonal antibody treatment of patients with COVID-19, Infect. Chemother, doi:10.3947/ic.2021.0304
Kim, Ryu, Lee, Kim, Seo et al., A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein, Nat. Commun, doi:10.1038/s41467-020-20602-5
Lee, Lee, Ko, Hyun, Kim et al., Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease, Front. Immunol, doi:10.3389/fimmu.2021.772320
Lee, Lee, Lee, Kim, Lee et al., Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: A propensity score-matched retrospective cohort study, Int. Immunopharmacol, doi:10.1016/j.intimp.2022.108570
Lee, Lim, Hong, Park, Kim et al., The primary report of clinical data analysis on the COVID-19 in the Republic of Korea, Public Health Wkly. Rep
Lee, Mcdonald, Butler-Laporte, Harrison, Cheng et al., Remdesivir and systemic corticosteroids for the treatment of COVID-19: A Bayesian re-analysis, Int. J. Infect. Dis, doi:10.1016/j.ijid.2021.01.065
Olivas-Martínez, Cárdenas-Fragoso, Jiménez, Lozano-Cruz, Ortiz-Brizuela et al., In-hospital mortality from severe COVID-19 in a tertiary care center in Mexico City; causes of death, risk factors and the impact of hospital saturation, PLoS ONE, doi:10.1371/journal.pone.0245772
Park, Epidemiology, virology, and clinical features of severe acute respiratory syndrome -coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19), Clin. Exp. Pediatr, doi:10.3345/cep.2020.00493
Regeneron, REGEN-COV™ (Casirivimab and Imdevimab) Phase 3 Recovery Trial Meets Primary Outcome, Improving Survival in Hospitalized COVID-19 Patients Lacking an Immune Response to SARS-COV-2
Rice, Wheeler, Bernard, Hayden, Schoenfeld et al., and Blood Institute ARDS Network. Comparison of the SpO 2 /FIO 2 ratio and the PaO 2 /FIO 2 ratio in patients with acute lung injury or ARDS, Chest, doi:10.1378/chest.07-0617
Ryu, Kang, Noh, Woo, Lee et al., The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2, Biochem. Biophys. Res. Commun, doi:10.1016/j.bbrc.2021.09.023
Sheikh, Mcmenamin, Taylor, Robertson, Public Health Scotland and the EAVE II Collaborators. SARS-CoV-2 Delta VOC in Scotland: Demographics, risk of hospital admission, and vaccine effectiveness, Lancet, doi:10.1016/S0140-6736(21)01358-1
Simonis, Serpa Neto, Binnekade, Braber, Bruin et al., Effect of a low vs intermediate tidal volume strategy on ventilator-free days in intensive care unit patients without ARDS: A randomized clinical trial, JAMA, doi:10.1001/jama.2018.14280
Taylor, Adams, Hufford, De La Torre, Winthrop et al., Neutralizing monoclonal antibodies for treatment of COVID-19, Nat. Rev. Immunol, doi:10.1038/s41577-021-00542-x
Ulrich, Troxel, Carmody, Eapen, Bäcker et al., Treating COVID-19 with hydroxychloroquine (TEACH): A multicenter, double-blind randomized controlled trial in hospitalized patients, Open Forum Infect. Dis, doi:10.1093/ofid/ofaa446
Waghmare, Xie, Kimball, Yi, Özkök et al., Supplemental oxygen-free days in hematopoietic cell transplant recipients with respiratory syncytial virus, J. Infect. Dis, doi:10.1093/infdis/jix390
Wang, Wang, Identification of risk factors for in-hospital death of COVID-19 pneumonia -lessions from the early outbreak, BMC Infect. Dis, doi:10.1186/s12879-021-05814-4
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention, JAMA, doi:10.1001/jama.2020.2648
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop